AbCellera Biologics (ABCL) said Monday the first patients were dosed in the phase 2 portion of its phase 1/2 trial of ABCL635, an experimental antibody to reduce the frequency and severity of vasomotor symptoms, or hot flashes, in postmenopausal women.

The second phase is a randomized, double-blind, placebo-controlled study in 80 women and follows an interim review of safety, tolerability and pharmacodynamic data from healthy volunteers in the first phase.

AbCellera said the phase 2 enrollment is underway and top-line clinical results for both phases are expected in Q3.

Shares of AbCellera Biologics were up 1.5% in recent trading.

Price: 4.44, Change: +0.06, Percent Change: +1.49